The LAMEA Diabetic Neuropathy Treatment Market would witness market growth of 9.6% CAGR during the forecast period (2024-2031).
The Brazil market dominated the LAMEA Diabetic Neuropathy Treatment Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $165 million by 2031.The Argentina market is showcasing a CAGR of 10.2% during (2024 - 2031). Additionally, The UAE market would register a CAGR of 9.3% during (2024 - 2031).
Diabetic neuropathy is a serious and debilitating complication of diabetes, affecting millions of people. It is distinguished by nerve damage induced by extended exposure to hyperglycemia. In particular, the hands and feet may experience numbness, pain, and weakness due to this condition.
Moreover, by increasing the likelihood of complications like foot ulcers and amputations and making it challenging to perform daily tasks, diabetic neuropathy can have a substantial negative effect on an individual's quality of life.
Similarly, with more individuals affected by diabetes and at risk of developing diabetic neuropathy, there is a heightened demand for this within Saudi Arabia. According to the International Diabetes Federation, 537 million people have diabetes and 73 million people in the MENA (Middle Esat and North Africa) region by 2045. This will rise to 135.7 million. In 2021, out of a total adult population of 24,194,300 in Saudi Arabia, there were approximately 4,274,100 cases of diabetes in adults, representing a prevalence rate of 17.7%.
Based on Distribution Channel, the market is segmented into Hospitals Pharmacies, Retail Pharmacies and Others. Based on Drug Class, the market is segmented into Non-Steroidal Anti-inflammatory Drugs (NSAIDs), Antidepressants, Opioid, Capsaicin and Others. Based on Disorder Type, the market is segmented into Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy and Focal Neuropathy. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The Brazil market dominated the LAMEA Diabetic Neuropathy Treatment Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $165 million by 2031.The Argentina market is showcasing a CAGR of 10.2% during (2024 - 2031). Additionally, The UAE market would register a CAGR of 9.3% during (2024 - 2031).
Diabetic neuropathy is a serious and debilitating complication of diabetes, affecting millions of people. It is distinguished by nerve damage induced by extended exposure to hyperglycemia. In particular, the hands and feet may experience numbness, pain, and weakness due to this condition.
Moreover, by increasing the likelihood of complications like foot ulcers and amputations and making it challenging to perform daily tasks, diabetic neuropathy can have a substantial negative effect on an individual's quality of life.
Similarly, with more individuals affected by diabetes and at risk of developing diabetic neuropathy, there is a heightened demand for this within Saudi Arabia. According to the International Diabetes Federation, 537 million people have diabetes and 73 million people in the MENA (Middle Esat and North Africa) region by 2045. This will rise to 135.7 million. In 2021, out of a total adult population of 24,194,300 in Saudi Arabia, there were approximately 4,274,100 cases of diabetes in adults, representing a prevalence rate of 17.7%.
Based on Distribution Channel, the market is segmented into Hospitals Pharmacies, Retail Pharmacies and Others. Based on Drug Class, the market is segmented into Non-Steroidal Anti-inflammatory Drugs (NSAIDs), Antidepressants, Opioid, Capsaicin and Others. Based on Disorder Type, the market is segmented into Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy and Focal Neuropathy. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
List of Key Companies Profiled
- Abbott Laboratories
- Eli Lilly And Company
- Pfizer, Inc.
- Lupin Limited
- Astellas Pharma, Inc.
- Glenmark Pharmaceuticals Limited
- Boehringer Ingelheim International GmbH
- Novartis AG
- McKesson Corporation
- GlaxoSmithKline PLC (GSK)
Market Report Segmentation
By Distribution Channel- Hospitals Pharmacies
- Retail Pharmacies
- Others
- Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
- Antidepressants
- Opioid
- Capsaicin
- Others
- Peripheral Neuropathy
- Autonomic Neuropathy
- Proximal Neuropathy
- Focal Neuropathy
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. LAMEA Diabetic Neuropathy Treatment Market by Distribution Channel
Chapter 5. LAMEA Diabetic Neuropathy Treatment Market by Drug Class
Chapter 6. LAMEA Diabetic Neuropathy Treatment Market by Disorder Type
Chapter 7. LAMEA Diabetic Neuropathy Treatment Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Abbott Laboratories
- Eli Lilly And Company
- Pfizer, Inc.
- Lupin Limited
- Astellas Pharma, Inc.
- Glenmark Pharmaceuticals Limited
- Boehringer Ingelheim International GmbH
- Novartis AG
- McKesson Corporation
- GlaxoSmithKline PLC (GSK)
Methodology
LOADING...
